Wet macular degeneration is a kind of long-lasting eye disorder that causes blurred vision or a blind spot in the central vision. It is generally caused by blood vessels that leak fluid or blood into the macula. This disease includes mild symptoms such as mild blurriness in the central vision or difficulty seeing in low lighting. In late AMD (wet or dry type), numerous people experience straight lines start to look wavy or crooked. A blurry area near the center of your vision is also observed.
The burden of wet age-related macular degeneration continues to rise at a high speed as the population increases and the demographics reflect a majority of older people. As per the National Eye Institute, AMD is a primary cause of visual loss in the elderly. Currently, only a few drugs, primarily anti-VEGFs, are approved for the treatment of age-related macular degeneration. Also, the eylea segment dominated the market in 2021, having a revenue share of over 50.0%.
Data Bridge Market Research analyses a growth rate in the wet age-related macular degeneration (AMD) market in the forecast period 2023-2030. The expected CAGR of wet age-related macular degeneration (AMD) market is tend to be around 6.8% in the mentioned forecast period. The market is valued at USD 107.5 million in 2022, and it would grow upto USD 181.9 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Read Full Report Summary @ https://www.databridgemarketresearch.com/reports/netherlands-wet-age-related-macular-degeneration-amd-market
There are various treatment drugs that help treat wet macular degeneration, which in turn increases the market's growth. For instance, in 2011, the FDA authorized Eylea, an intravitreal injection of aflibercept. It stops VEGF from working in wet AMD. Patients suffering from diabetic macular edema, wet AMD, and macular edema are well-treated with it. Furthermore, patients who received Beovu witnessed four times greater intraocular inflammation than the ones who received Eylea. Such elements influence people to choose Eylea over Beovu. Thus, this factor increases the growth of the market.
Key players operating in the wet age-related macular degeneration (AMD) market include:
Loop Road Holdings LLC (U.S.)
Old Saw Mill Holdings LLC (U.S.)
OSMR LLC (U.S.)
Regeneron Capital International B.V. (Netherlands)
Regeneron International Limited (Ireland)
F. Hoffmann-La Roche Ltd (Switzerland)
Novartis AG (Switzerland)
Bayer AG (Germany)
About Data Bridge Market Research, Private Ltd
Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.
Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”
Contact:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Corporatesales@databridgemarketresearch.com
